Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dabigatran Etexilate · 1 trial · 1 indication
AUC0-t was calculated according to the mixed log linear trapezoidal rule.
AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).
Cmax was obtained directly from the concentration versus time curve.
| Arm | Type | Description |
|---|---|---|
| Dabigatran Etexilate | EXPERIMENTAL | - |
| Tepotinib + Dabigatran | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Dabigatran Etexilate | DRUG | Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2. |
| Tepotinib | DRUG | Participants received single oral dose of Tepotinib for 8 days in Treatment period 2. |
Inclusion Criteria: * Healthy participants of non-child bearing potential * Body weight between 50 to 100 kilogram (kg) * Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\^2) * A male participant must agree to use and to have his female partner of childbearing potential t...